Jax DiEugenio

A United Kingdom Conformity Assessed marking was granted to the Avantect Multi-Cancer Detection Test and Avantect Ovarian Cancer Test.

An indirect comparison of SEQUOIA and CLL14 shows zanubrutinib improved PFS over venetoclax/obinutuzumab in treatment-naive CLL after baseline adjustment.

The SCOPE score was predictive of response, toxicity, and survival outcomes in patients with relapsed/refractory myeloma receiving BCMA CAR T-cell therapy.

Theresa Medina, MD, discusses 5-year C-144-01 results with lifileucel in advanced melanoma.

INESSS has issued a positive recommendation for the reimbursement of subcutaneous nivolumab across all Health Canada–authorized solid tumor indications.

Manali Kamdar, MD, discusses advances with CAR T-cell therapy in B-cell malignancies and the monitoring needs for CRS and ICANS that affect patient access.

The FDA approved subcutaneous pembrolizumab for use in adult and pediatric solid tumor indications approved for intravenous pembrolizumab.

An HMR risk signature predicted outcomes in multiple myeloma, linked with genomic instability, immune microenvironment, and drug sensitivity.

T-DXd demonstrated durable systemic and intracranial responses in patients with HER2-positive, -low, and -zero breast cancer brain metastases.

Raludotatug deruxtecan earned FDA breakthrough designation for CDH6-expressing platinum-resistant ovarian cancers after bevacizumab treatment.

Experts preview abstracts being presented at IMS, highlighting the role of MRD, bispecific antibodies, and other strategies to refine myeloma management.

Five-year data show cemiplimab plus chemotherapy delivers durable OS, ORR, and DOR benefits in advanced NSCLC.

Tepotinib treatment was characterized by frequent but manageable TRAEs in MET exon 14–positive NSCLC, with peripheral edema as the most common toxicity.

Perioperative tislelizumab plus chemotherapy showed sustained OS and EFS improvement vs chemotherapy in resectable NSCLC.

Taletrectinib delivered high response rates and durable benefit with manageable safety in ROS1-positive non–small cell lung cancer.

Results from the ALCHEMIST trial show that adjuvant crizotinib did not improve DFS or OS vs observation in resected ALK-positive NSCLC.

The addition of aumolertinib to chemotherapy improved PFS vs aumolertinib monotherapy for the treatment of patients with EGFR-mutated NSCLC.

First-line iza-bren plus osimertinib demonstrated a manageable safety profile with preliminary antitumor activity in EGFR-mutant NSCLC.

The MMR IHC Panel pharmDx was certified in the EU as a companion diagnostic to identify patients with colorectal cancer eligible for nivolumab/ipilimumab.

Health Canada approved mirvetuximab soravtansine for folate receptor-alpha positive, platinum-resistant epithelial ovarian cancer.

The European Medicines Agency has granted orphan drug designation to OXC-101 for the treatment of acute myeloid leukemia.

The FDA granted breakthrough device designation to the Haystack MRD ctDNA liquid biopsy for stage II colorectal cancer.

The FDA has approved a 3-month version of leuprolide mesylate for patients with advanced prostate cancer.

Glenn J. Hanna, MD, discusses the preliminary antitumor activity and safety profile of micvotabart pelidotin in head and neck squamous cell carcinoma.

Experts preview key abstracts to watch at the IASLC 2025 World Conference on Lung Cancer.

R. Lor Randall, MD, FACS, discusses prosthetic design, embodiment strategies, and research to enhance function post-amputation in sarcoma management.

Stenoparib receives FDA fast track designation for the treatment of patients with advanced ovarian cancer.

David Olmos, MD, PhD, discusses how data on the incidence of HRR alterations in metastatic prostate cancer can inform future research.